Notably, a recent study demonstrated reduced stem cell activity in response to Notch1 or Notch4 suppression using the same breast cancer cell lines described herein [9], which supports the use of gamma-secretase inhibitors in clinical trials [47]. The gene discussed is NOTCH4; the disease is breast cancer.